Antineoplastons (Burzynski clinic)
Antineoplastons are peptide fractions first isolated from urine and given at one private clinic in Texas for nearly fifty years, mostly to children with brain tumours. Despite dozens of registered trials, none has been published in full, no independent group has confirmed benefit, and the treatment is expensive and causes serious salt imbalance.
Overview
Stanislaw Burzynski proposed in the 1970s that antineoplastons, peptides and amino-acid derivatives (A10, AS2-1, related to phenylacetate and phenylacetylglutamine), correct a natural biochemical defence against cancer. The Burzynski Research Institute has registered more than 60 phase 2 trials since the 1990s, almost all in brain tumours; none has been completed and published as a full report, and the only independent attempt, an NCI-sponsored trial in the 1990s, was terminated after disputes over eligibility with too few patients to analyse. Case reports of response are unverified, and hypernatraemia, sometimes severe, is a recognised toxicity. Patients pay large sums for treatment on a trial basis. The FDA and the Texas Medical Board have taken repeated action. The NCI PDQ summary concludes that no randomised controlled trials show benefit.
How it works
Claimed restoration of a peptide-based anticancer defence system; the compounds are metabolites of phenylbutyrate, a drug tested and abandoned elsewhere for cancer.
- Registered trials exist, so results could in principle be published
- No published completed trial in five decades
- Severe hypernatraemia
- Very high cost to patients
Latest papers
topQuery for this technology: (TITLE:"Antineoplastons" OR ABSTRACT:"Antineoplastons" OR TITLE:"Burzynski clinic" OR ABSTRACT:"Burzynski clinic") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Antineoplastons (Burzynski clinic), not a curated reading list.
Pages like this
not linked directly; found by shared links- TechnologyEssiac, Hoxsey and other 'herbal cancer cures'
Shares Alternative medicine used instead of standard treatment, Evidence-based integrative oncology, Misinformation and unproven therapies and the tags complementary, supportive-care, evidence:insufficient.
- TechnologyFenbendazole, ivermectin and other internet 'repurposed cures'
Shares Alternative medicine used instead of standard treatment, Evidence-based integrative oncology, Misinformation and unproven therapies and the tags complementary, supportive-care, evidence:insufficient.
- TechnologyMistletoe extracts (Iscador, Helixor)
Shares Evidence-based integrative oncology, Misinformation and unproven therapies, Failures are hidden and the tags complementary, supportive-care, evidence:insufficient.
- TechnologyReiki, healing touch and other energy therapies
Shares Evidence-based integrative oncology, Misinformation and unproven therapies and the tags complementary, supportive-care, evidence:insufficient.
- TechnologyHigh-dose intravenous vitamin C
Shares Evidence-based integrative oncology, Misinformation and unproven therapies, Glioma & glioblastoma and the tags complementary, supportive-care, evidence:insufficient.
- TechnologyCurcumin and turmeric
Shares Evidence-based integrative oncology, Misinformation and unproven therapies and the tags complementary, supportive-care, evidence:insufficient.
- TechnologyHomeopathy
Shares Evidence-based integrative oncology, Misinformation and unproven therapies and the tags complementary, supportive-care, evidence:insufficient.
- TechnologyAyurvedic medicine and cancer
Shares Evidence-based integrative oncology, Misinformation and unproven therapies and the tags complementary, supportive-care, evidence:insufficient.